



CrystalGenomics, Inc.

www.crystalgenomics.com/en

CrystalGenomics is a commercial stage biopharmaceutical company dedicated to the R&D and commercialization of novel pharmaceuticals to address significant unmet medical needs in the therapeutic area of infectious disease, oncology and inflammatory diseases. CrystalGenomics has a marketed product, Acelex (Polmacoxib), which has been approved by the MFDS and several export agreements has been signed with several countries. In addition to Acelex, CrystalGenomics is developing several first-in class/best-in class drug candidates.

Main Products



Acelex Tablet



Acelex Capsule

Products (Ingredient/Formulation)	Use	Exporting Countries
Acelex (Polmacoxib) 2mg Capsule	Nonsteroidal anti-inflammatory drug for osteoarthritis	Turkey & MENA 19 countries, Brazil, Eurasian Economic Union (Russia, Belarus, Kazakhstan, Kyrgyzstan, Armenia)
Acelex (Polmacoxib) 2mg Tablet	Nonsteroidal anti-inflammatory drug for osteoarthritis	

CEO
Joong Myung Cho

Location
CrystatGenomics, Inc., 5th F, Bldg A, Korea Bio Park, 700, Daewangpangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Republic of Korea

Specialty
1. Inflammatory disease
2. Oncology
3. Infectious disease

Tel / Fax / E-mail
T. 82-31-628-2720
F. 82-31-628-2701

R&D Pipeline

Area	Program	Indications	Preclinical	Ph 1	Ph 2	Ph 3
Pain/ Inflammation	CG-650	Acute/Chronic Pain				
	CG-651 ⁽¹⁾	Neuropathic Pain				
	CG-598 ⁽²⁾	Inflammatory Bowel Disease				
Anti- Infective	CG-549 ⁽¹⁾	MRSA		Global Clinical trial		
Oncology	Ivaltinostat ⁽²⁾	Pancreatic Cancer		MFDS/FDA Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	MDS		MFDS Orphan Drug Designation		
	Ivaltinostat ⁽²⁾	AML			Global Clinical trial	
	Ivaltinostat + Anti-PD-1 Antibody	HCC ⁽¹⁾			Global Clinical trial	
	CG-806 ⁽¹⁾	AML, MCL, CLL		APTISE BIOSCIENCES	Global Clinical trial	
Fibrosis	CG-750 ⁽²⁾	Fibrosis				

(1) First-in-class
(2) Best-in-class